RxSight Q4 2023 Adj EPS $(0.13) Beats $(0.36) Estimate, Sales $28.58M Beat $27.43M Estimate
Portfolio Pulse from Benzinga Newsdesk
RxSight (NASDAQ:RXST) reported Q4 2023 adjusted EPS of $(0.13), surpassing the $(0.36) estimate, with sales of $28.58M exceeding the $27.43M forecast. This represents a 77.65% increase in sales compared to the same period last year.
February 28, 2024 | 9:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RxSight reported a significant beat on both EPS and sales estimates for Q4 2023, with a notable year-over-year sales growth of 77.65%.
Beating both EPS and sales estimates significantly, especially with a substantial year-over-year sales increase, typically leads to positive investor sentiment and could boost the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100